[Role of plasminogen activators in the treatment of deep venous thrombosis].
In deep vein thrombosis, thrombolytic agents can improve vein patency more rapidly than conventional anticoagulant therapy. The clinical benefit of thrombolytic use would be a reduction in the incidence and severity of the postthrombotic syndrome and limb salvage in "phlegmatia caerulea". A literature review suggests that streptokinase and rt-PA do better than heparin regarding vein patency. A clinical benefit on postthrombotic syndrome can only be suggested by available evidence. The risk of major bleeding is increased by thrombolytic agents as compared with heparin. Mortality for cerebral bleeding is about 0.5%. Currently, thrombolytic therapy is only recommended for limb salvage in phlegmatia caerulea.
Bollaert
P E
PE
Service de réanimation médicale, hôpital Central, 54035 Nancy, France. pe.bollaert@chu-nancy.fr
D002543:Cerebral Hemorrhage / Q000139:chemically induced; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D023821:Limb Salvage; D010960:Plasminogen Activators / Q000009:adverse effects / Q000627:therapeutic use*; D011186:Postphlebitic Syndrome / Q000188:drug therapy / Q000517:prevention & control*; D016032:Randomized Controlled Trials as Topic; D013924:Thrombophlebitis / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000009:adverse effects / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator